Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.

Al-Marrawi, M. Y.,Saroya, B. S.,Brennan, M. C.,Yang, Z.,Dykes, T. M.,El-Deiry, W. S.; Cancer Biol. Ther.. 2013 Jun 25.

The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients.

Al-Marrawi, M. Y.,Rini, B. I.,Harshman, L. C.,Bjarnason, G.,Wood, L.,Vaishampayan, U.,Mackenzie, M.,Knox, J. J.,Agarwal, N.,Al-Harbi, H.,Kollmannsberger, C.,Tan, M. H....; Target Oncol. 2013 Sep.

Pazopanib for the treatment of renal cancer.

Al-Marrawi, M. Y., Rini, B.; Expert Opin Pharmacother. 2011 May.